Bayer AG’s failure to identify weaknesses in Merck & Co.’s over the counter drug business before it bought it in 2014 sets a problematic precedent for its latest acquisition, an M&A expert told me today. Why? Read my piece for the Wall Street Journal’s CFO Journal. 

A U.S. investigation into the lack of write-downs at Exxon Mobil Corp. despite the slump in oil-prices has brought to light the challenge of assessing impairments under U.S. Generally Accepted Accounting Principles (GAAP). But, for international companies and U.S. firms with foreign operations, figuring out GAAP is not the only contest. For the Wall Street Journal’s CFO Journal, I have taken a closer look at write-downs under GAAP vs. IFRS.

Finally! The British government has given the green light for the new nuclear reactor in Somerset. The project could either bolster or wreck EDF, the majority shareholder. Why? I have taken a closer look at the financials of the deal.

Luka Mucic in effect has two positions at SAP AG. He officially serves as the enterprise management software giant’s finance chief while also, less formally, overseeing the venture capital fund the company launched a generation ago. Sapphire Ventures LLC on Wednesday announced fresh capital commitments of $1 billion. For my new story, Mr. Mucic explained what SAP wants from its offspring.

t is the biggest foreign acquisition in the history of corporate Germany. For the Wall Street Journal’s CFO Journal, I haven taken a closer look at the financing of the Bayer Monsanto tie-up.